{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:03:24Z","timestamp":1793437404753,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40273-025-01488-x","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:44:50Z","timestamp":1745430290000},"page":"805-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-3540","authenticated-orcid":false,"given":"Nick","family":"Jovanoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6240-9923","authenticated-orcid":false,"given":"Sarah","family":"Vaselenak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3443-6894","authenticated-orcid":false,"given":"Andrew","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Turki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-3126","authenticated-orcid":false,"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"3","key":"1488_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1488_CR2","unstructured":"Ferlay JE, Lam M, Laversanne F, Colombet M, Mery M, Pi\u00f1eros L, Znaor M, Soerjomataram A, Bray I. Global Cancer Observatory: Cancer Today. 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed July 2024."},{"key":"1488_CR3","unstructured":"Canadian Cancer Society. Canadian Cancer Statistics 2023. https:\/\/www.lung.ca\/lung-health\/lung-diseases\/lung-cancer\/about-lung-cancer-lung-cancer-canada. Accessed July 2024."},{"issue":"3","key":"1488_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cllc.2016.12.010","volume":"18","author":"MR Sung","year":"2017","unstructured":"Sung MR, Patel MV, Djalalov S, Le LW, Shepherd FA, Burkes RL, et al. Evolution of symptom burden of advanced lung cancer over a decade. Clin Lung Cancer. 2017;18(3):274-80.e6.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"1488_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1188\/13.ONF.337-346","volume":"40","author":"M Grant","year":"2013","unstructured":"Grant M, Sun V, Fujinami R, Sidhu R, Otis-Green S, Juarez G, et al. Family caregiver burden, skills preparedness, and quality of life in non-small cell lung cancer. Oncol Nurs Forum. 2013;40(4):337\u201346.","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"1488_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465\u201372.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1488_CR7","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.9778\/cmajo.20170144","volume":"6","author":"C de Oliveira","year":"2018","unstructured":"de Oliveira C, Weir S, Rangrej J, Krahn MD, Mittmann N, Hoch JS, et al. The economic burden of cancer care in Canada: a population-based cost study. CMAJ Open. 2018;6(1):E1-e10.","journal-title":"CMAJ Open"},{"issue":"4","key":"1488_CR8","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/curroncol29040223","volume":"29","author":"R Garaszczuk","year":"2022","unstructured":"Garaszczuk R, Yong JHE, Sun Z, de Oliveira C. The economic burden of cancer in Canada from a societal perspective. Curr Oncol (Toronto, Ont). 2022;29(4):2735\u201348.","journal-title":"Curr Oncol (Toronto, Ont)."},{"issue":"12","key":"1488_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2217\/fon-2021-1417","volume":"18","author":"N Waser","year":"2022","unstructured":"Waser N, Vo L, McKenna M, Penrod JR, Goring S. Real-world treatment patterns in resectable (stages I-III) non-small-cell lung cancer: a systematic literature review. Future Oncol (London, England). 2022;18(12):1519\u201330.","journal-title":"Future Oncol (London, England)."},{"key":"1488_CR10","unstructured":"National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer, Version 1.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"12","key":"1488_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"issue":"2","key":"1488_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.athoracsur.2006.08.046","volume":"83","author":"H Sugimura","year":"2007","unstructured":"Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83(2):409\u201318.","journal-title":"Ann Thorac Surg"},{"key":"1488_CR13","doi-asserted-by":"crossref","unstructured":"Shimizu R, Kinoshita T, Sasaki N, Uematsu M, Sugita Y, Shima T, et al. Clinicopathological factors related to recurrence patterns of resected non-small cell lung cancer. J Clin Med. 2020;9(8):2473.","DOI":"10.3390\/jcm9082473"},{"issue":"6","key":"1488_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.athoracsur.2012.03.031","volume":"93","author":"MD Taylor","year":"2012","unstructured":"Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93(6):1813\u201321.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"1488_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/djv059","volume":"107","author":"D Consonni","year":"2015","unstructured":"Consonni D, Pierobon M, Gail MH, Rubagotti M, Rotunno M, Goldstein A, et al. Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Inst. 2015;107(6):59.","journal-title":"J Natl Cancer Inst"},{"key":"1488_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.lungcan.2018.07.042","volume":"124","author":"C Chouaid","year":"2018","unstructured":"Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, et al. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer (Amsterdam, Netherlands). 2018;124:310\u20136.","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"issue":"8","key":"1488_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1200\/JCO.2002.08.092","volume":"20","author":"J Martin","year":"2002","unstructured":"Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol. 2002;20(8):1989\u201395.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1488_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cllc.2019.12.001","volume":"21","author":"CM Karacz","year":"2020","unstructured":"Karacz CM, Yan J, Zhu H, Gerber DE. Timing, sites, and correlates of lung cancer recurrence. Clin Lung Cancer. 2020;21(2):127-35.e3.","journal-title":"Clin Lung Cancer"},{"key":"1488_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.lungcan.2018.06.007","volume":"124","author":"S Andreas","year":"2018","unstructured":"Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer (Amsterdam, Netherlands). 2018;124:298\u2013309.","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"key":"1488_CR20","doi-asserted-by":"crossref","unstructured":"Jovanoski N, Bowes K, Brown A, Belleli R, Di Maio D, Chadda S, et al. Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence. J Lung Cancer Manag. 2023;12(3):LMT60.","DOI":"10.2217\/lmt-2023-0003"},{"key":"1488_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","volume":"114","author":"HX Tian","year":"2017","unstructured":"Tian HX, Zhang XC, Yang JJ, Guo WB, Chen ZH, Wang Z, et al. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer (Amsterdam, Netherlands). 2017;114:90\u20135.","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"issue":"2","key":"1488_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.21037\/tlcr-22-631","volume":"12","author":"MF Chen","year":"2023","unstructured":"Chen MF, Chaft JE. Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review. Transl Lung Cancer Res. 2023;12(2):337\u201345.","journal-title":"Transl Lung Cancer Res"},{"issue":"10026","key":"1488_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415\u201326.","journal-title":"Lancet"},{"key":"1488_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lungcan.2018.05.020","volume":"122","author":"JE Chaft","year":"2018","unstructured":"Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer (Amsterdam, Netherlands). 2018;122:67\u201371.","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"issue":"4","key":"1488_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217\u201337.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"1488_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer (Amsterdam, Netherlands). 2015;88(1):108\u201311.","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"issue":"1","key":"1488_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12916-021-02207-x","volume":"20","author":"Z Zou","year":"2022","unstructured":"Zou Z, Xing P, Hao X, Wang Y, Song X, Shan L, et al. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med. 2022;20(1):12.","journal-title":"BMC Med"},{"issue":"21","key":"1488_CR28","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552\u20139.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1488_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390(14):1265\u201376.","journal-title":"N Engl J Med"},{"issue":"6","key":"1488_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100612","volume":"7","author":"R Dziadziuszko","year":"2022","unstructured":"Dziadziuszko R, Peters S, Ruf T, Cardona A, Guerini E, Kurtsikidze N, et al. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open. 2022;7(6):100612.","journal-title":"ESMO open."},{"key":"1488_CR31","doi-asserted-by":"crossref","unstructured":"Horinouchi H, Solomon BJ, Wu Y-L, Barlesi F, Nishio M, Ahn JS, et al. ALINA safety results: adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC). WCLC. 2024.","DOI":"10.1016\/j.jtho.2024.09.070"},{"issue":"16_suppl","key":"1488_CR32","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2024.42.16_suppl.8006","volume":"42","author":"M Nishio","year":"2024","unstructured":"Nishio M, Wu Y-L, Barlesi F, Ahn JS, Lee DH, Lee J-S, et al. Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA. J Clin Oncol. 2024;42(16_suppl):8006.","journal-title":"J Clin Oncol"},{"key":"1488_CR33","unstructured":"EU EMA. Alecensa. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alecensa. Accessed 20 Dec 2024."},{"key":"1488_CR34","unstructured":"US FDA. Alecensa (Alectinib) Prescribing Information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208434s015lbl.pdf. Accessed 20 Dec 2024."},{"key":"1488_CR35","unstructured":"Canada's Drug Agency (CDA). Alectinib. 2024. https:\/\/www.cda-amc.ca\/alectinib. Accessed 18 Sept 2024."},{"key":"1488_CR36","unstructured":"Canada's Drug Agency (CDA). Atezolizumab. 2025. https:\/\/www.cda-amc.ca\/atezolizumab. Accessed 25 Feb 2025."},{"issue":"5","key":"1488_CR37","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0178","volume":"13","author":"C Balijepalli","year":"2024","unstructured":"Balijepalli C, Gullapalli L, Joshy J, Rawson NS. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health. J Comp Eff Res. 2024;13(5): e230178.","journal-title":"J Comp Eff Res."},{"key":"1488_CR38","unstructured":"Canada's Drug Agency (CDA). Reimbursement review provisional funding algorithm indication: anaplastic lymphoma kinase\u2013positive non\u2013small cell lung cancer 2022. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/PH0009-ALK%2BNSCLC-Algorithm.pdf. Accessed 28 July 2024."},{"key":"1488_CR39","unstructured":"Statistics Canada. Life Tables, Canada, Provinces and Territories 2023002. 2023. https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/84-537-X. Accessed 28 July 2024."},{"issue":"6","key":"1488_CR40","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/j.cllc.2017.05.005","volume":"18","author":"S Nakamichi","year":"2017","unstructured":"Nakamichi S, Horinouchi H, Asao T, Goto Y, Kanda S, Fujiwara Y, et al. Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer developing after surgery. Clin Lung Cancer. 2017;18(6):e441\u20138.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"1488_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","volume":"14","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated alk-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233\u201343.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1488_CR42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in alk inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091\u2013108.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1488_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354\u201366.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1488_CR44","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazi\u00e8res J, Oh IJ, de Castro J, Migliorino MR, Helland \u00c5, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409\u201316.","journal-title":"Ann Oncol"},{"key":"1488_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2016.11.002","volume":"102","author":"ML Wong","year":"2016","unstructured":"Wong ML, McMurry TL, Stukenborg GJ, Francescatti AB, Amato-Martz C, Schumacher JR, et al. Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study. Lung Cancer (Amsterdam, Netherlands). 2016;102:108\u201317.","journal-title":"Lung Cancer (Amsterdam, Netherlands)."},{"issue":"1","key":"1488_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","volume":"54","author":"F Xie","year":"2016","unstructured":"Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98\u2013105.","journal-title":"Med Care"},{"issue":"8","key":"1488_CR47","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","volume":"8","author":"C Chouaid","year":"2013","unstructured":"Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997\u20131003.","journal-title":"J Thorac Oncol"},{"key":"1488_CR48","unstructured":"Ontario Ministry of Health. Schedule of Benefits. 2023. https:\/\/www.ontario.ca\/files\/2024-01\/moh-ohip-schedule-of-benefits-2024-01-24.pdf. Accessed July 2024."},{"issue":"2","key":"1488_CR49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.lungcan.2014.09.013","volume":"86","author":"AL Mahar","year":"2014","unstructured":"Mahar AL, Coburn NG, Johnson AP. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2014;86(2):281\u20137.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"2","key":"1488_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3747\/co.26.4555","volume":"26","author":"SJ Seung","year":"2019","unstructured":"Seung SJ, Hurry M, Hassan S, Walton RN, Evans WK. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol (Toronto, Ont). 2019;26(2):102\u20137.","journal-title":"Curr Oncol (Toronto, Ont)."},{"key":"1488_CR51","unstructured":"Cancer Care Ontario. Lung cancer follow-up care pathway map. 2017. https:\/\/www.cancercareontario.ca\/sites\/ccocancercare\/files\/assets\/LungFollow-upCarePathwayMap.pdf. Accessed 20 Dec 2024."},{"issue":"2","key":"1488_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/082585971102700203","volume":"27","author":"H Walker","year":"2011","unstructured":"Walker H, Anderson M, Farahati F, Howell D, Librach SL, Husain A, et al. Resource use and costs of end-of-Life\/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care. 2011;27(2):79\u201388.","journal-title":"J Palliat Care"},{"key":"1488_CR53","unstructured":"Statistics Canada. Labour force characteristics by province, monthly, seasonally adjusted. 2024. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410028703. Accessed 28 July 2024."},{"key":"1488_CR54","unstructured":"Statistics Canada. Income of individuals by age group, sex and income source, Canada, provinces and selected census metropolitan areas 2023. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1110023901. Accessed 28 July 2024."},{"issue":"6","key":"1488_CR55","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.3390\/curroncol31060251","volume":"31","author":"Q Chu","year":"2024","unstructured":"Chu Q, Sripada K, Vaselenak S, Jovanoski N, Arnold M. Impact of adjuvant atezolizumab on recurrences avoided and treatment cost savings for patients with stage II-IIIA non-small cell lung cancer in Canada. Current Oncology (Toronto, Ont). 2024;31(6):3301\u201310.","journal-title":"Current oncology (Toronto, Ont)."},{"issue":"3","key":"1488_CR56","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s41669-023-00396-0","volume":"7","author":"A Verhoek","year":"2023","unstructured":"Verhoek A, Cheema P, Melosky B, Samson B, Shepherd FA, de Marinis F, et al. Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer. PharmacoEconomics Open. 2023;7(3):455\u201367.","journal-title":"PharmacoEconomics Open."},{"key":"1488_CR57","unstructured":"Jovanoski N, Yip CY. The Cost-Effectiveness of adjuvant atezolizumabfor the treatment of stage II-IIIA, PD-L1 TC \u2265 50%, NSCLC: a comparison of methods for modelling health state transitions following disease-free survival. ISPOR-EU (2023). Copenhagen, Denmark."},{"issue":"1","key":"1488_CR58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12890-022-01936-w","volume":"22","author":"J Yuan","year":"2022","unstructured":"Yuan J, Cheng Z, Feng J, Xu C, Wang Y, Zou Z, et al. Prognosis of lung cancer with simple brain metastasis patients and establishment of survival prediction models: a study based on real events. BMC Pulm Med. 2022;22(1):162.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"1488_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000414","volume":"3","author":"N Girard","year":"2018","unstructured":"Girard N, Cozzone D, de Leotoing L, Tournier C, Vainchtock A, Tehard B, et al. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open. 2018;3(6):e000414.","journal-title":"ESMO open."},{"key":"1488_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.lungcan.2018.03.008","volume":"119","author":"C Burudpakdee","year":"2018","unstructured":"Burudpakdee C, Wong W, Seetasith A, Corvino FA, Yeh W, Gubens M. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2018;119:103\u201311.","journal-title":"Lung cancer (Amsterdam, Netherlands)."},{"issue":"5","key":"1488_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101438","volume":"9","author":"J Crooks","year":"2024","unstructured":"Crooks J, Dominic O, Shepard M, Yu A, Liang Y, Karlovits SM, et al. Cost of treatment for brain metastases using data from a national health insurance. Adv Radiat Oncol. 2024;9(5): 101438.","journal-title":"Adv Radiat Oncol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01488-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T11:02:05Z","timestamp":1749898925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01488-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01488-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"20 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, and open access for the publication of this article, were funded by F. Hoffmann-La Roche Ltd. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Sean R Mills and Laura Vergoz, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Substantial contributions to the conception or design of the work: all authors. Data analysis: N.J., S.V., A.H., and J.T. Interpretation of data for the work: all authors. Drafting the work or reviewing it critically for important intellectual content: all authors. Final approval of the version to be published: all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributor"}},{"value":"Nick Jovanoski, Sarah Vaselenak, Andrew Hogan, Jasmine Turki: employment at Roche; Nick Jovanoski, Andrew Hogan: holds stocks at Roche; Quincy Chu: honoraria from consultation with AbbVie, Amgen, AnHeart, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genprex, GSK, Janssen, Merck, Novartis, Ocellaris, Pfizer, Roche, and Takeda, research fundings from AstraZeneca and Roche, and former Data and Safety Monitoring Board member for Merck KgaA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"For eligible studies qualified researchers may request access to individual patient level clinical data through a data request platform. At the time of writing this request platform is Vivli. . For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here:\u202f. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked owing to a potential increase in risk of patient re-identification.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}